全文获取类型
收费全文 | 20519篇 |
免费 | 1926篇 |
国内免费 | 1252篇 |
专业分类
耳鼻咽喉 | 189篇 |
儿科学 | 292篇 |
妇产科学 | 243篇 |
基础医学 | 2273篇 |
口腔科学 | 388篇 |
临床医学 | 2619篇 |
内科学 | 2952篇 |
皮肤病学 | 233篇 |
神经病学 | 986篇 |
特种医学 | 682篇 |
外国民族医学 | 3篇 |
外科学 | 2167篇 |
综合类 | 3667篇 |
现状与发展 | 4篇 |
一般理论 | 6篇 |
预防医学 | 1634篇 |
眼科学 | 509篇 |
药学 | 1934篇 |
23篇 | |
中国医学 | 1324篇 |
肿瘤学 | 1569篇 |
出版年
2024年 | 85篇 |
2023年 | 329篇 |
2022年 | 851篇 |
2021年 | 1032篇 |
2020年 | 757篇 |
2019年 | 603篇 |
2018年 | 677篇 |
2017年 | 581篇 |
2016年 | 561篇 |
2015年 | 809篇 |
2014年 | 918篇 |
2013年 | 1029篇 |
2012年 | 1511篇 |
2011年 | 1584篇 |
2010年 | 1124篇 |
2009年 | 990篇 |
2008年 | 1237篇 |
2007年 | 1216篇 |
2006年 | 1193篇 |
2005年 | 1016篇 |
2004年 | 788篇 |
2003年 | 770篇 |
2002年 | 666篇 |
2001年 | 504篇 |
2000年 | 518篇 |
1999年 | 419篇 |
1998年 | 253篇 |
1997年 | 215篇 |
1996年 | 169篇 |
1995年 | 189篇 |
1994年 | 144篇 |
1993年 | 79篇 |
1992年 | 133篇 |
1991年 | 110篇 |
1990年 | 84篇 |
1989年 | 72篇 |
1988年 | 76篇 |
1987年 | 67篇 |
1986年 | 52篇 |
1985年 | 44篇 |
1984年 | 36篇 |
1983年 | 24篇 |
1982年 | 18篇 |
1981年 | 15篇 |
1980年 | 18篇 |
1979年 | 31篇 |
1977年 | 16篇 |
1973年 | 11篇 |
1972年 | 10篇 |
1971年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
Gregory A Hale Laura C Bowman Richard J Rochester Eli Benaim Helen E Heslop Robert A Krance Edwin M Horwitz John M Cunningham Xin Tong Deo Kumar Srivastava Rupert Handgretinger Deborah P Jones 《Biology of blood and marrow transplantation》2005,11(11):912-920
Hemolytic uremic syndrome (HUS) is an uncommon but potentially life-threatening complication of hematopoietic stem cell transplantation. We retrospectively studied the medical records of 293 children who underwent allogeneic bone marrow transplantation at St. Jude Children's Research Hospital between 1992 and 1999 to describe the clinical course of and to identify risk factors for transplant-associated HUS. Conditioning regimens included cyclophosphamide, cytarabine, and total body irradiation for patients with hematologic malignancies (n = 244); patients with nonmalignant diseases (n = 49) received disease-specific regimens. Grafts from unrelated or mismatched related donors were depleted of T lymphocytes, whereas matched sibling grafts were unmanipulated. All patients received cyclosporine as prophylaxis for graft-versus-host disease. Recipients of grafts from matched siblings also received pentoxifylline or short-course methotrexate. HUS developed in 28 (9.6%) patients at a median of 171 days after transplantation. We identified older donor age (P = .029), use of antithymocyte globulin in the conditioning regimen (P = .008), and recipient CMV seronegativity (P = .011) as being associated with an increased risk of HUS. With a multiple regression analysis, the use of antithymocyte globulin (beta = .86; P = .04) and recipient cytomegalovirus seronegativity (beta = .93; P = .035) remained significant risk factors for the development of HUS. 相似文献
63.
64.
G M Clark Y C Tong J F Patrick P M Seligman P A Crosby J A Kuzma D K Money 《Journal of medical engineering & technology》1984,8(1):3-8
A multi-channel cochlear implant hearing prosthesis providing 22 separate channels of stimulation has been developed. The electronics for the implantable receiver-stimulator have been incorporated on a single chip, using digital circuits and employing CMOS technology. The chip is enclosed in a titanium capsule with platinum/ceramic electrode feed-throughs. A pocket-sized speech processor and directional microphone extract the following speech parameters: signal amplitude, fundamental frequency and formant frequency. The fundamental frequency is coded as electric pulse rate, and formant frequency by electrode position. The speech processor has been realized using hybrid circuits and CMOS gate arrays. The multi-channel prosthesis has undergone a clinical trial on four postlingually deaf patients with profound-total hearing losses. The speech perception results indicate that they were able to obtain open-set speech recognition scores for phonetically balanced words, CID sentences and spondees. In all cases the tests showed significant improvements when using the cochlear prosthesis combined with lipreading compared to lipreading alone. 相似文献
65.
Jinyi Yuan Biwen Mo Zhuang Ma Yuan Lv Shih-Lung Cheng Yanping Yang Zhaohui Tong Renguang Wu Shenghua Sun Zhaolong Cao Jufang Wu Demei Zhu Liwen Chang Yingyuan Zhang 《Journal of microbiology, immunology, and infection》2019,52(1):35-44
Background/Purpose
Nemonoxacin is a novel nonfluorinated quinolone with excellent in vitro activity against most pathogens in community-acquired pneumonia (CAP), especially Gram-positive isolates. The purpose of this study was to assess the efficacy and safety of nemonoxacin compared with levofloxacin in patients with CAP.Methods
A phase 3, multicenter, randomized (2:1) controlled trial was conducted in adult CAP patients receiving nemonoxacin 500 mg or levofloxacin 500 mg orally once daily for 7–10 days. Clinical, microbiological response and adverse events were assessed. Non-inferiority was determined in terms of clinical cure rate of nemonoxacin compared with that of levofloxacin in a modified intention-to-treat (mITT) population. NCT registration number: NCT01529476.Results
A total of 527 patients were randomized and treated with nemonoxacin (n = 356) or levofloxacin (n = 171). The clinical cure rate at test-of-cure visit was 94.3% (300/318) for nemonoxacin and 93.5% (143/153) for levofloxacin in the mITT population [difference (95% CI), 0.9% (?3.8%, 5.5%)]. The microbiological success rate was 92.1% (105/114) for nemonoxacin and 91.7% (55/60) for levofloxacin in the bacteriological mITT population [difference (95% CI), 0.4% (?8.1%, 9.0%)]. The incidence of adverse events (AEs) was comparable between nemonoxacin (33.1%, 118/356) and levofloxacin (33.3%, 57/171) (P > 0.05).Conclusion
Nemonoxacin 500 mg once daily for 7–10 days is as effective and safe as levofloxacin for treating adult CAP patients in terms of clinical cure rates, microbiological success rates, and safety profile.ClinicalTrials.gov identifier: NCT01529476. 相似文献66.
卵巢宫内膜样腺癌的病理组织学及组织化学分析 总被引:1,自引:0,他引:1
本文通过对24肺卵巢宫内膜样腺癌的巨检,镜及组织化学染色等结果分析,提出按该瘤所含组织成分,将其分为单纯型及混合型两大类。单纯型中分化程度不同又再分成Ⅰ,Ⅱ,ⅢⅣ级。混合型中根据所含成分又再分为腺棘癌,腺鳞癌,透明细胞腺癌型,含粘液腺癌型及含浆液腺癌型。讨论了该瘤的临床表现,发病率,组织来源,病理特征,诊断步骤及各类型与预后之间的关系。 相似文献
67.
本文研究了骨水泥三种不同临床使用方法所形成的内部气泡结构状态,测定了骨水泥的抗压强度、收缩率、疲劳强度、变形积累量等物理机械性能,以及关节固定强度,用气泡状态解释了不同临床使用方法对骨水泥性能及固定强度所带来的各种影响。 相似文献
68.
以51例晚期肿瘤患者作为研究对象,对其不同来源的肿瘤浸润淋巴细胞(TIL)进行治疗研究,发现肿瘤组织来源的TIL其有效率及一年生存率明显高于胸腹水及转移淋巴结的TAL;其中肿瘤组织的TIL,胸腹水、转移淋巴结的TAL有效率分别为80.9%、40.0%、46.6%;三者治疗肿瘤患者的一年生存率分别为81.0%、46.7%、60.0%;另外发现胸腹水TAL对实质性肿块治疗疗效较低,为40%,其中静脉滴 相似文献
69.
以~3H地塞米松(Dex)为特异性配基,以一点分析法测得大白鼠腹腔中性粒细胞(PMNs)的糖皮质激素受体(GCR)位点数为5270±216/个PMN(n=18,X±SE下同);体外实验,PMNs直接与山莨菪碱(654-23×10~(-5)M)温育,对GCR无明显影响,测得位点数为4896±360/个PMNs(n=20,P>0.4);体内实验表明,给大鼠肌肉注射654-2(10mg/kg)每日两次共二天,则GCR位点数降至2740±101/个PMNs(n=18,P<0.001)。此时还测得血浆皮质酮含量明显增高(P<0.01)。提示654-2对GCR的影响可能与增加皮质激素所致的“降调节”有关。 相似文献
70.
BACKGROUND: Isolated detection of hepatitis B core antibody (anti-HBc) in the absence of surface antigen (HBsAg) or antibody (anti-HBs) has been reported, particularly among individuals infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). The significance of this phenomenon is unknown and it is unclear whether all individuals with such serological pattern need further molecular investigations. OBJECTIVES: To determine the prevalence of 'anti-HBc only' in samples referred to a clinical virology laboratory and to evaluate its significance and possible mechanisms. STUDY DESIGN: Samples identified as anti-HBc positive (389/4359, 8.9%) during an 11-month period were investigated for HBsAg, anti-HBs, anti-HCV and anti-HIV. 'Anti-HBc only' samples were tested for HBV DNA using a nested qualitative PCR. Viral loads were measured in samples with detectable HBV DNA and the DNA sequences were analysed. RESULTS: Of 379 samples with detectable anti-HBc, 155 (40.9%) were 'anti-HBc only'. HBV DNA was detected in 6/151 (4%), all of which had a viral load <400 copies per ml. Anti-HIV was found in 50/151 (33.1%) and anti-HCV in 14/151 (9.3%). Of these, only one of the HIV infected patients had detectable HBV DNA. Phylogenetic analysis of the HBV surface gene from three patients showed a variety of genotypes (A, E and G). One sequence had a mutation in codon 144, which has previously been reported to give false negative HBsAg results. CONCLUSIONS: 'Anti-HBc only' is a common phenomenon in the clinical virology laboratory but only a small proportion of samples had detectable HBV DNA. The presence of HBsAg mutants with possible false negative HBsAg test result is of concern. Samples with 'anti-HBc only' could be used to monitor the emergence of these mutants. 相似文献